ライフサイエンスコーパス: hypertension

1 n the cardiovascular response to exercise in hypertension.

2 zole concentrations, older age, and baseline hypertension.

3 n the mechanisms linking type 1 diabetes and hypertension.

4 ng and pharmacogenomics for the treatment of hypertension.

5 g the sympathetic nervous system and causing hypertension.

6 ed a group-based intervention to people with hypertension.

7 denervation were previously shown to reduce hypertension.

8 licate it in the pathogenesis of "essential" hypertension.

9 =15 mm Hg without another cause of pulmonary hypertension.

10 asodilation is a hallmark of obesity-induced hypertension.

11 oregulatory outcomes of septic patients with hypertension.

12 (DBP) in individuals with prehypertension or hypertension.

13 suggest that immune cells may play a role in hypertension.

14 in human and experimental pulmonary arterial hypertension.

15 creation is an accepted treatment of portal hypertension.

16 usted for age, sex, BMI, smoking status, and hypertension.

17 w drug targets in the treatment of pulmonary hypertension.

18 ceptor signaling causes inflammation-induced hypertension.

19 olic tissues and is linked to renin-mediated hypertension.

20 unction, participates in the pathogenesis of hypertension.

21 had at least 1 comorbidity and 509 (49%) had hypertension.

22 ces enrolled 3,200 patients with established hypertension.

23 d as a potential cause of the dysfunction in hypertension.

24 HR that may contribute to the development of hypertension.

25 reason to avoid or de-escalate treatment for hypertension.

26 e vascular NADPH oxidases under diabetes and hypertension.

27 of white-coat effect and masked uncontrolled hypertension.

28 rease peripheral vascular resistance causing hypertension.

29 h the development of aging-induced essential hypertension.

30 on is associated with obesity, diabetes, and hypertension.

31 cle cells confirmed that mutant PDE3A causes hypertension.

32 FN-EDA contribute to TGFbeta2 induced ocular hypertension.

33 ring may be the best approach for diagnosing hypertension.

34 al drug target, primarily for the control of hypertension.

35 c oedema that resemble signs of intracranial hypertension.

36 not pulmonary disease, immunocompromise, or hypertension.

37 hronic inflammatory mouse model of pulmonary hypertension.

38 pontaneously hypertensive rat (SHR) model of hypertension.

39 iable in individuals with prehypertension or hypertension.

40 fter PEA in chronic thromboembolic pulmonary hypertension.

41 d with cardiovascular disease, diabetes, and hypertension.

42 ompared with the 3026 (22%) patients without hypertension.

43 and fibrosis of the kidney in salt-sensitive hypertension.

44 ibute to disc hemorrhage formation in ocular hypertension.

45 rt3 protects vascular function and decreases hypertension.

46 eatment, and hospital referral of women with hypertension.

47 renin-independent aldosterone production and hypertension.

48 sk stratification of patients with pulmonary hypertension.

49 ligious services were less likely to develop hypertension.

50 ages, including before the onset of systemic hypertension.

51 Sirt3 expression in vascular dysfunction and hypertension.

52 I 1.5 to 3.7), smoking (2.1, 1.2 to 3.6) and hypertension (1.6, 1.0 to 2.5) were independently predic

53 62 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin

54 0.002) and were more likely to have systemic hypertension (17.7% vs. 33.8%, P < 0.001), tumor locatio

55 ly), diarrhea (4% and 7%, respectively), and hypertension (21% and 10%, respectively); grade 3 or 4 i

56 Of the 101 patients, hypertension (38, 37.6%), cardiovascular disease (21,20.

57 compared with 2.6%; p = 0.001), preexisting hypertension (4.3% compared with 1.5%; p = 0.0041), and

58 s 19.9%; standardized difference, 0.15), and hypertension (53.4% vs 62.9%; standardized difference, 0

59 dities were present in 55% of patients, with hypertension (59%), obesity (47%), cardiovascular diseas

60 ontrols, PHOMS were observed in intracranial hypertension (62%), optic disc drusen (47%), anomalous o

61 CHA(2)DS(2)-VASc (congestive heart failure, hypertension, 65 years of age and older, diabetes mellit

62 The most common adverse events (AEs) were hypertension (69%), proteinuria (51%), and diarrhea and

63 ts) were neutropenia (14%), pneumonia (11%), hypertension (7%), anemia (7%), and diarrhea (5%).

64 billion [95% CI, $67.6-$90.8 billion]), and hypertension ($79.0 billion [95% CI, $72.6-$86.8 billion

65 with hypoxic-ischemic brain injury had more hypertension (8 vs 4; p = 0.047), a higher day 1 lactate

66 was 71, 61.8% were male, white (87.2%), had hypertension (83.7%), hyperlipidemia (72.1%), diabetes m

67 most common grade 3 or 4 adverse events were hypertension (88 [27%] of 332 patients in the experiment

68 ug/24 h (CI, 5.6 to 8.9 mug/24 h) in stage 1 hypertension, 9.5 mug/24 h (CI, 8.2 to 10.8 mug/24 h) in

69 Such models of preclinical pulmonary hypertension, a disease of the pulmonary vasculature tha

70 diet is associated with metabolic syndrome, hypertension, abdominal obesity, and hypertriglyceridemi

71 core was 4.6 +/- 1.5, and the mean HAS-BLED (hypertension, abnormal renal/liver function, stroke, ble

72 structure and function and prevent pulmonary hypertension after intrauterine inflammation is controve

73 to describe trends in maternal pre-pregnancy hypertension among women in rural and urban areas in 200

74 sure (IOP) in patients with glaucoma, ocular hypertension, anatomic narrow angles, and in glaucoma su

75 as 2.04 (95% CI: 0.93, 4.47) for gestational hypertension and 1.11 (95% CI: 0.63, 1.93) for pre-eclam

76 measurement on a single occasion to diagnose hypertension and a single blood glucose measurement to d

77 There are few studies assessing pre-hypertension and an impaired fasting glucose (IFG) and t

78 links to stroke for focusing the framework: hypertension and atrial fibrillation.

79 This treatment suppressed CKD-induced hypertension and cardiac hypertrophy.

80 ersity Hospital, assessed the association of hypertension and CCB use with all-cause and infection-re

81 Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and per

82 associations persisted after adjustment for hypertension and diabetes mellitus.

83 ality clinical care received by patients for hypertension and diabetes.

84 at contribute to sympathetic overactivity in hypertension and discuss their potential for therapeutic

85 e factors have extensive global effects (eg, hypertension and education), others (eg, household air p

86 g complication of pregnancy characterised by hypertension and elevated soluble Fms-Like Tyrosine Kina

87 enting and managing chronic diseases such as hypertension and emerging infectious diseases such as co

88 Portal hypertension and esophageal varices needing treatment co

89 rillopathy, which often presents with ocular hypertension and exfoliation glaucoma (XFG).

90 te significantly to the higher prevalence of hypertension and greater cardiometabolic risk in older w

91 Low SES is a risk factor for hypertension and high blood pressure (BP).

92 inherited disorder characterized by arterial hypertension and hyperkalemia with metabolic acidosis.

93 Posaconazole is associated with secondary hypertension and hypokalemia, consistent with pseudohype

94 strate a new paradigm for the development of hypertension and imply that the trafficking protein SNX1

95 titis (AH) with advanced fibrosis and portal hypertension and in experimental mouse fibrosis.

96 kidney disease, renal fibrosis, renovascular hypertension and kidney cancer.

97 ications include the diagnosis of white-coat hypertension and masked hypertension and the identificat

98 Masked uncontrolled hypertension and mean 24-hour BP associated with high ri

99 investigated the association of a history of hypertension and office systolic blood pressure (SBP) wi

100 and leads to cellular signals, which promote hypertension and organ damage, and ultimately progressiv

101 enetic conditions (such as systemic arterial hypertension and phaeochromocytoma), which variously lea

102 Comorbidities such as anemia or hypertension and physiological factors related to exerti

103 ents, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).

104 y the association between early postdonation hypertension and recipient graft failure using propensit

105 rotein SNX1 may be a crucial determinant for hypertension and response to antihypertensive therapy.

106 African American Study of Kidney Disease and Hypertension and the Atherosclerosis Risk in Communities

107 gnosis of white-coat hypertension and masked hypertension and the identification of white-coat effect

108 data, including from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).

109 women; mean age, 50.3+/-6.3 years) with mild hypertension and with low cardiovascular risk and 24 hea

110 ified (also known as idiopathic intracranial hypertension), and secondary pseudotumor cerebri, in whi

111 g/24 h (CI, 8.2 to 10.8 mug/24 h) in stage 2 hypertension, and 14.6 mug/24 h (CI, 12.9 to 16.2 mug/24

112 es, especially among patients suffering from hypertension, and a longer delay to treatment, which may

113 ses such as type 2 diabetes mellitus (T2DM), hypertension, and dyslipidaemia.

114 control systemic diseases such as diabetes, hypertension, and dyslipidaemia.

115 isk factors such as use of tobacco products, hypertension, and general obesity are also discussed.

116 ger cold/warm ischemia time, recipient/donor hypertension, and having a male donor were identified as

117 Y7 were associated with black race, smoking, hypertension, and higher body mass index.

118 sively investigated device-based therapy for hypertension, and randomized, sham-controlled trials hav

119 ass index, high-income region of enrollment, hypertension, and tenofovir disoproxil fumarate.

120 -Gprc5b-KO mice were protected from arterial hypertension, and this protective effect was abrogated b

121 nes, extramedullary hematopoiesis, pulmonary hypertension, and thrombosis, are related to the chronic

122 blished CKD risk factors, including obesity, hypertension, and type 2 diabetes.

123 ith graft failure, the reported diagnosis of hypertension as determined by the requirement for blood

124 y genetically linked with pulmonary arterial hypertension, as a major component of the mammalian poly

125 Hypertension awareness, treatment, and control programs

126 maternal age, obesity, diabetes mellitus and hypertension become more common in the pregnant populati

127 While hypertension (beta=2.259; P=0.015) was an independent de

128 Prevalence of hypertension (both primary and secondary) in children an

129 For example, BPV is elevated in hypertension but reduced under anesthesia.

130 ssion contributes to vascular dysfunction in hypertension, but increased Sirt3 protects vascular func

131 Exercise in patients with hypertension can be accompanied by an abnormal cardiovas

132 Telemonitoring for hypertension can be implemented into routine primary car

133 ercalated cells, and plays a crucial role in hypertension, cardiovascular disease, kidney disease, an

134 ificant comorbidities, the most common being hypertension, chronic kidney disease, obstructive sleep

135 ctivity and to a dramatic increase in portal hypertension compared to BDL in wild-type mice.

136 4 h (CI, 12.9 to 16.2 mug/24 h) in resistant hypertension; corresponding adjusted prevalence estimate

137 th residual chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy (PEA

138 Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of pulmonary arterial

139 illance for chronic thromboembolic pulmonary hypertension (CTEPH), with ventilation-perfusion scannin

140 ce scores for the Dietary Approaches to Stop Hypertension (DASH) and Alternate Mediterranean (AMED) d

141 lity based on the Dietary Approaches to Stop Hypertension (DASH) score and dietary inflammatory poten

142 endations and the Dietary Approaches to Stop Hypertension (DASH) with the risk of pre-eclampsia and G

143 s [Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Pro-vegetarian dietary pattern]

144 Pulmonary artery hypertension decreased 8[13, 4] mmHg, as did vascular re

145 Individuals classed as grade 1 hypertension demonstrated higher retinal arterial baseli

146 x, mean blood pressure and comorbidity (i.e. hypertension, diabetes and dyslipidemia).

147 =40 years) who had never been diagnosed with hypertension, diabetes mellitus (DM), and cancer before.

148 r AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index,

149 Hypertension, diabetes with chronic complications, and o

150 disease, various cardiomyopathies, obesity, hypertension, diabetes, and chronic kidney disease) and

151 h Chinese Americans, older age, male gender, hypertension, diabetes, greater axial length (AL), bigge

152 k factors assessed at baseline were smoking, hypertension, diabetes, obesity and physical inactivity.

153 Included covariates were age, hypertension, diagnoses including obesity, alcohol, slee

154 t brain-mediated mechanisms are different in hypertension during SI.

155 s related diseases, such as type 2 diabetes, hypertension, dyslipidemia, and sleep apnea, are very co

156 g/m2 (3.6), 60.1% females] without diabetes, hypertension, dyslipidemia, the metabolic syndrome or im

157 ng 4 criteria (elevated waist circumference, hypertension, elevated plasma glucose level, and dyslipi

158 nce of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of

159 ed risk factors such as diabetes mellitus or hypertension, emerging risk factors such as sleep apnea

160 This indicates that preexisting hypertension exacerbates the development of secondary ne

161 es are responsible for familial hyperkalemic hypertension (FHHt), a rare, inherited disorder characte

162 ports intensive BP lowering in patients with hypertension for improving cardiovascular outcomes.

163 For hypertension, GDP and HDI were both positively associate

164 It is proposed that obesity-related hypertension has a neurogenic component which is charact

165 By contrast, the prevalence of hypertension has increased, especially in low- and middl

166 Maternal burden of pre-pregnancy hypertension has nearly doubled in the past decade and t

167 Patterns of reporting for obesity, hypertension, heart conditions, or hypercholesterolemia

168 ciated with low RGS2 protein levels, such as hypertension, heart failure, and anxiety.

169 s, anesthesia type, inpatient status, portal hypertension history, and variable complication reportin

170 d adjustment for race, obesity, tobacco use, hypertension (HTN), atrial fibrillation (AF), and chroni

171 ikely to have diabetes mellitus (p = 0.004), hypertension, hyperlipidemia, and chronic kidney disease

172 graft had at least one comorbidity, such as hypertension, hyperlipidemia, or coronary artery disease

173 Risks for pre-hypertension/hypertension and inflammation were also gre

174 re genomics, explore the causal pathways for hypertension identified in Mendelian randomization studi

175 de III or IV aortic regurgitation, pulmonary hypertension) identified patients at high risk of HF rea

176 (PTC-T) and those of idiopathic intracranial hypertension (IIH) are absent in the literature.

177 -Oncology, Coronary Disease & Interventions, Hypertension, Imaging, Metabolic & Lipid Disorders, Neur

178 r randomised controlled trial of people with hypertension in 3 rural regions of South India, each at

179 growth and function, and prevents pulmonary hypertension in a rat model of chorioamnionitis-induced

180 iation between hypertension in childhood and hypertension in adulthood.

181 onal studies indicate an association between hypertension in childhood and hypertension in adulthood.

182 it is unknown if there are true controls for hypertension in epidemiological and genetic studies.

183 rapeutic target, for aging-induced essential hypertension in humans.

184 , depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and

185 HAPE to HVPG measurements to diagnose portal hypertension in participants undergoing a transjugular l

186 correlated with disease severity and portal hypertension in patients with AH.

187 mbulatory BP monitoring in the evaluation of hypertension in patients with CKD.

188 interventions targeting women with pregnancy hypertension in three low-income countries.

189 Ad5.TGFbeta2 induced ocular hypertension in wildtype C57BL/6J mice and further ampli

190 mon adverse events of grade 3 or higher were hypertension (in 21% of the patients), increased alanine

191 d a CNS-penetrant generic medication used in hypertension, indapamide, as we found it to have antioxi

192 lled BP, the presence of masked uncontrolled hypertension independently associated with higher risk o

193 However, comparison with gestational hypertension indicates that additional factors modify th

194 membrane localization are upregulated during hypertension induced by angiotensin II (AngII).

195 ught to determine whether baseline pulmonary hypertension influences outcomes of transcatheter mitral

196 ting an integrated telemonitoring system for hypertension into routine primary care.

197 ociety of Anesthesiologists (ASA) >2, portal hypertension, intraoperative blood transfusions, and cen

198 trolling for age, body mass index, diabetes, hypertension, intubation, and RRT.

199 ries (PAAF) of idiopathic pulmonary arterial hypertension (IPAH) patients and healthy donors.

200 isolated from idiopathic pulmonary arterial hypertension (IPAH) patients compared to those from heal

201 Hypertension is a common modifiable risk factor for card

202 Although hypertension is a leading risk factor for dementia, how

203 Maternal hypertension is associated with adverse pregnancy outcom

204 The most frequent cause of portal hypertension is cirrhosis.

205 The burden of hypertension is escalating, and control rates are poor i

206 Exercise pulmonary hypertension is independently associated with CV event-f

207 Arterial hypertension is the most prevalent modifiable risk facto

208 signaling contributes to the development of hypertension is uncertain.

209 ach of these processes in the development of hypertension is unclear.

210 ommon drug used in the treatment of systemic hypertension, it is important for cardiologists, general

211 disease 2019, including male sex, history of hypertension, low peripheral blood, and elevated broncho

212 e (eg, cytopenias, liver dysfunction, portal hypertension, malabsorption, and weight loss).

213 The mechanisms by which obesity and hypertension may synergistically induce macrophage metab

214 vidual-patient data from 187,552 people with hypertension (mean age 48.1 years, 53.5% female) living

215 ertriglyceridemia, obesity, type 2 diabetes, hypertension, metabolic syndrome), but the mechanism und

216 response to Ang II (angiotensin II)-mediated hypertension, miR-214 showed the highest induction (8-fo

217 preserved visual function in a mouse ocular hypertension model.

218 onditions (ie, heart failure/cardiomyopathy, hypertension, myocardial infarction, atrial fibrillation

219 For eyes with ocular hypertension (n = 45) at baseline, the incidence of POAG

220 coronary artery disease (n=31), 33% arterial hypertension (n=75), and 12% diabetes mellitus type II (

221 tus and its related comorbidities, including hypertension, obesity, and heart failure (HF).

222 (odds ratio, 6.41 [95% CI, 2.95-15.56]) and hypertension (odds ratio, 2.86 [95% CI, 1.39-6.17]) were

223 Hypertension often occurs before renal function deterior

224 cular pressure (IOP) in patients with ocular hypertension (OHT) or glaucoma.

225 plies to adults 18 years or older with known hypertension or elevated blood pressure, those with dysl

226 ent) that involved more than 500 adults with hypertension or elevated BP and that were 6 months or lo

227 erestimate complications arising from portal hypertension or infection.

228 with COVID-19 diagnosis among patients with hypertension or with mortality or severe disease among p

229 =.0004), ALT (OR=3.13 per doubling, P=.003), hypertension (OR=10.93, P=.002), hyperlipidemia (OR=4.36

230 al activity, physical functioning, diabetes, hypertension, or coronary heart disease.

231 ce of diabetes mellitus (P = 0.16), arterial hypertension (P = 0.45), chronic obstructive pulmonary d

232 % CI: 0.86, 0.97) showed a decreased risk of hypertension (P for trend = 0.001).

233 requent comorbidities, DM complications, and hypertension (P value < .05).

234 Pulmonary arterial hypertension (PAH) is a fatal disease characterized by p

235 Pulmonary arterial hypertension (PAH) is a lethal vasculopathy.

236 Pulmonary arterial hypertension (PAH) is a rare, fatal, and incurable disor

237 Pulmonary Arterial Hypertension (PAH) is overrepresented in People Living w

238 In pulmonary arterial hypertension (PAH), endothelial dysfunction and oblitera

239 Another is pulmonary arterial hypertension (PAH), where gravitational gradients may be

240 racteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, and transplant-free s

241 ial/ethnic differences in pulmonary arterial hypertension (PAH).Objectives: Determine effects of race

242 velop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among other compli

243 are unlikely to benefit group 2/3 pulmonary hypertension patients and may cause harm.

244 e emphasized to reduce the risk of CVD among hypertension patients.

245 act of COC on CVD risk among newly-diagnosed hypertension patients.

246 However, persistent pulmonary hypertension (PH) after PEA remains a major determinant

247 onchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) after preterm birth.

248 Pulmonary hypertension (PH) associated with left heart disease, or

249 Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type

250 ated as a therapeutic strategy for pulmonary hypertension (PH) in experimental models of PH.

251 Pulmonary hypertension (PH) is a feature of a variety of diseases

252 Rationale: Pulmonary hypertension (PH) is a life-threatening cardiopulmonary

253 Pulmonary hypertension (PH) is characterized by pulmonary artery r

254 ibitors (PDE5i) for groups 2 and 3 pulmonary hypertension (PH) is rising nationally, despite guidelin

255 g of the pulmonary vasculature and pulmonary hypertension (PH).

256 Untreated portopulmonary hypertension (PoPH) carries a poor prognosis.

257 ranted to test implementation strategies for hypertension prevention and control, especially in low-i

258 enced participants with cirrhosis and portal hypertension, prior liver transplantation (LT) or severe

259 Patients with hypertension receiving at least 2 medications at maximum

260 riatric surgery on patients with obesity and hypertension remain uncertain.

261 were number of antihypertensive medications, hypertension remission, and BP control according to curr

262 low-density lipoprotein cholesterol levels, hypertension, renal disease, age, and sex.

263 Alcohol diagnosis, diabetes, hypertension, sleep apnea, prior MI and IHD (all P<0.001

264 Age, sex, dyslipidemia, hypertension, smoking, and family history of premature c

265 arrow environment that supports residence of hypertension-specific CD8(+) T cells.

266 n-style and DASH [Dietary Approaches to Stop Hypertension]-style diets) that are inherently relativel

267 - 0.1 for T2*, whereas for participants with hypertension these dynamic T2 and T2* values had a mean

268 tment of patients with diabetes mellitus and hypertension to slow and stabilize coronary artery disea

269 sed, treated, or controlled) for diabetes or hypertension, to indicate outcomes of provision of quali

270 rategies and programs implemented to improve hypertension treatment and control have been extraordina

271 h a body mass index of 25 kg/m(2), no use of hypertension treatment and no history of heart failure h

272 corneal thickness of subjects in the Ocular Hypertension Treatment Study (OHTS) and determined if ce

273 with a body mass index of 30 kg/m(2), use of hypertension treatment, and with prevalent heart failure

274 role of hypoxia-inducible factors (HIFs) in hypertension, type 2 diabetes (T2D), and cognitive decli

275 k factor for common disease states including hypertension, type 2 diabetes mellitus, and chronic kidn

276 tients with chronic thromboembolic pulmonary hypertension undergoing PEA to predict postoperative out

277 nts per center; three centers) with arterial hypertension underwent standardized 3-T baseline MRI ass

278 region and adjusted for baseline control of hypertension (using intention-to-treat principles).

279 nism whereby TNFR1 activation contributes to hypertension via heightened hypothalamic glutamate-depen

280 Multivariable analysis revealed that hypertension was associated with increased mortality due

281 Hypertension was defined as prescription of blood pressu

282 A clinical history of arterial hypertension was present in 10 857 (78%) participants, a

283 A history of hypertension was present in 4357 patients (34.6%), among

284 n healthy participants and participants with hypertension was significant for both T2 (P < .001) and

285 Hypertension was the most common comorbidity (67.6%), an

286 g BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-la

287 017% vs 41% in 2005 consider candidates with hypertension well controlled with 1 medication.

288 f healthy participants and participants with hypertension were compared by using a nonparametric Mann

289 tudy, 23474 individuals without diabetes and hypertension were included in the present study.

290 Therefore, eight volunteers diagnosed with hypertension were studied during exercise with either sa

291 reased hypothermia is observed in neurogenic hypertension, which is caused by reduced hypothalamic pr

292 diagnosis of any kind of glaucoma or ocular hypertension who were aged >=40 years, were taking >=1 g

293 For example, only 12% of patients with hypertension with a high BP measurement during an ambula

294 fine this segment as a mutational hotspot in hypertension with brachydactyly.

295 analogous to a human deletion, recapitulates hypertension with brachydactyly.

296 Diabetes with chronic complications, hypertension with chronic complications, and obesity wer

297 ted diuresis and natriuresis are impaired in hypertension with unknown mechanism.

298 ssess the prevalence and financial burden of hypertension worldwide.

299 ing NADPH oxidase (Nox) genes associate with hypertension, yet target validation has been negative.

300 nflammation is critical for the emergence of hypertension, yet the mechanisms by which inflammatory m